Christobel Selecky Sells 50,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Christobel Selecky also recently made the following trade(s):

• On Tuesday, January 20th, Christobel Selecky sold 25,000 shares of ImmunityBio stock. The stock was sold at an average price of $7.51, for a total transaction of $187,750.00.

ImmunityBio Price Performance

NASDAQ IBRX opened at $7.34 on Friday. The company’s 50 day simple moving average is $2.65 and its two-hundred day simple moving average is $2.55. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $8.28. The stock has a market capitalization of $7.23 billion, a PE ratio of -17.90 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to analysts’ expectations of $31.88 million. On average, research analysts anticipate that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Institutional Investors Weigh In On ImmunityBio

A number of hedge funds have recently made changes to their positions in the business. TigerOak Management L.L.C. bought a new position in shares of ImmunityBio during the 4th quarter valued at $33,000. Wealth Management Associates Inc. purchased a new stake in ImmunityBio during the fourth quarter valued at about $38,000. Cherry Creek Investment Advisors Inc. bought a new position in shares of ImmunityBio during the fourth quarter valued at about $28,000. MOR Wealth Management LLC purchased a new position in shares of ImmunityBio in the fourth quarter worth about $494,000. Finally, Hennion & Walsh Asset Management Inc. lifted its stake in shares of ImmunityBio by 31.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 402,639 shares of the company’s stock valued at $797,000 after acquiring an additional 95,855 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA discussions gave a clearer path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer; ImmunityBio plans additional analyses and a filing soon. Read More.
• Positive Sentiment: HC Wainwright reaffirmed bullish coverage and raised long‑term outlook (FY2030 EPS estimate to $0.68), signaling rising analyst optimism about the company’s commercial prospects. Read More.
• Positive Sentiment: Recent company announcements about clinical results and an expansion plan have been cited in coverage characterizing the move as a strong rally, which has attracted momentum buyers. Read More.
• Neutral Sentiment: Short‑seller pain and a multi‑day rally are amplifying volume and volatility; technical short covering can sustain gains short‑term but doesn’t guarantee fundamentals. Read More.
• Neutral Sentiment: Multiple outlets note the stock’s extended run (reported as a 12‑day advance in some coverage), suggesting momentum trading is a significant component of the move. Read More.
• Negative Sentiment: Company insiders have sold shares recently (director Christobel Selecky and director Barry J. Simon among reported transactions), which investors often view as a caution signal on near‑term risk. Read More.
• Negative Sentiment: High‑profile commentators (e.g., Jim Cramer) have advised trimming positions and taking profits, highlighting opinion that the recent run may be speculative. Read More.
• Negative Sentiment: Some analysts warn momentum risks and that regulatory requests could require more data or time than investors expect — a potential downside if the sBLA resubmission is delayed or expanded. Read More.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on IBRX shares. BTIG Research reiterated a “buy” rating on shares of ImmunityBio in a research report on Thursday. D. Boral Capital reissued a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research note on Tuesday. Piper Sandler raised their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday. Jefferies Financial Group lifted their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.00.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.